Medical Xpress
DECEMBER 13, 2024
People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.
Pharmaceutical Technology
DECEMBER 13, 2024
The US FDA has accepted Sobi North Americas avatrombopag (DOPTELET) sNDA to treat paediatric immune thrombocytopenia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medical Xpress
DECEMBER 13, 2024
A new screening method that combines laser analysis with a type of AI is the first of its kind to identify patients in the earliest stage of breast cancer, a study suggests.
Pharmaceutical Technology
DECEMBER 13, 2024
Conduit has signed an agreement with Sarborg to leverage advanced artificial intelligence and cybernetics.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Medical Xpress
DECEMBER 13, 2024
The devastating news of a cancer diagnosis understandably makes doctors and patients focus on the cancer itself. However, experts in cardio-oncology from the European Society of Cardiology (ESC) emphasize that heart and cardiovascular health must be included as early as possible in the patient's cancer treatment plan to ensure the best possible outcomes.
Pharmaceutical Technology
DECEMBER 13, 2024
Roches Vabysmo is now available in prefilled syringes and vials for three retinal conditions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 13, 2024
New eClinical platforms from Merative are helping clinical trials develop effective randomization strategies.
Medical Xpress
DECEMBER 13, 2024
Researchers are shining a light on cancer cells' energy centersliterallyto damage these power sources and trigger widespread cancer cell death. In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells. Experiments showed the targeted therapy is effective at shrinking glioblastoma brain tumors and aggressive breast cancer tumors in mice.
Pharmaceutical Technology
DECEMBER 13, 2024
AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.
Medical Xpress
DECEMBER 13, 2024
Researchers at the University of Bergen have used advanced stem cell technology to develop mini-brains, also called brain organoids, that can mimic disease processes caused by mitochondrial failure. This could open new avenues for treating serious brain diseases such as epilepsy.
Pharmaceutical Technology
DECEMBER 13, 2024
AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy (FSHD).
Medical Xpress
DECEMBER 13, 2024
Scientists from the National Reference Center for Vibrios and Cholera at the Institut Pasteur, in collaboration with the Center hospitalier de Mayotte, have revealed the spread of a highly drug-resistant cholera strain. The study was published on December 11, 2024 in the New England Journal of Medicine.
Pharmaceutical Technology
DECEMBER 13, 2024
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer.
Medical Xpress
DECEMBER 13, 2024
Intermittent fasting has proven benefits for metabolic health, but a new study shows that it could slow hair growthat least in mice. Researchers report December 13 in the journal Cell that mice subjected to intermittent fasting regimes showed improved metabolic health but slower hair regeneration compared to mice with 24/7 access to food.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 13, 2024
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).
Medical Xpress
DECEMBER 13, 2024
A newly developed tool that harnesses computer vision and artificial intelligence (AI) may help clinicians rapidly evaluate placentas at birth, potentially improving neonatal and maternal care, according to new research from scientists at Northwestern Medicine and Penn State.
Pharmaceutical Technology
DECEMBER 13, 2024
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.
Medical Xpress
DECEMBER 13, 2024
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.
Pharmaceutical Technology
DECEMBER 13, 2024
JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Renal Cell Carcinoma;Metastatic Transitional (Urothelial) Tract Cancer.
Medical Xpress
DECEMBER 13, 2024
A research team has developed an innovative photocurrent-responsive implant surface to accelerate bone-to-implant integration after orthopedic surgery. The cutting-edge coating has been shown to shorten the integration time to just two weeks, doubling the speed and expediting post-operative recovery, as well as reducing the risk of rejection.
Pharmaceutical Technology
DECEMBER 13, 2024
Epinephrine is a small molecule commercialized by Aquestive Therapeutics, with a leading Phase III program in Anaphylaxis.
Medical Xpress
DECEMBER 13, 2024
Led by researchers from the University of Oxford's Leverhulme Center for Demographic Science and the University of Iceland, a review, published in Nature Aging, explores how genetic variations can explain differences in reproductive health and longevity.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
DECEMBER 13, 2024
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.
XTalks
DECEMBER 13, 2024
The DREAMM-7 Phase III trial has spotlighted the potential of Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) to improve survival outcomes for relapsed or refractory multiple myeloma. Blenrep was previously withdrawn from the US market in 2022 after the DREAMM-3 trial failed to confirm its initial accelerated approval.
Pharmaceutical Technology
DECEMBER 13, 2024
TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.
Medical Xpress
DECEMBER 13, 2024
Australian-led research is unlocking new ways for immunotherapy to better target cancer. Cancer immunotherapy has revolutionized treatment for patients, whereby the body's own immune system is harnessed to destroy cancer cells.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 13, 2024
FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.
Medical Xpress
DECEMBER 13, 2024
Mental health challenges are a significant and growing concern for the nation's farmers, according to the U.S. Department of Agriculture (USDA). As much as farming is often a family affair, programs and resources to support mental health in agriculture have focused on the primary producers, of whom nearly 64% are men. Women have always played a crucial role in agriculture, yet, Penn State Associate Professor Florence Becot said, their mental health and well-beingmuch like their essential contrib
Pharmaceutical Technology
DECEMBER 13, 2024
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer.
Medical Xpress
DECEMBER 13, 2024
Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreirorespectively, head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Center's Radiology Departmenthave shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancr
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
70 
Let's personalize your content